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BENEFITS OF MASSIVE WEIGHT LOSS ON SYMPTOMS, SYSTEMIC
INFLAMMATION AND CARTILAGE TURNOVER IN OBESE PATIENTS WITH
KNEE OSTEOARTHRITIS
P. Richette1, C. Poitou2, P. Garnero3, E. Vicaut1, J.-L. Bouillot4,
J.-M. Lacorte2, A. Basdevant2, K. Clément2, T. Bardin1, X. Chevalier5
1Hôpital Lariboisière, Paris, France; 2Hôpital La Pitié, Paris, France; 3Inserm
664, Lyon, France; 4Hôpital Hotel-Dieu, Paris, France; 5Hôpital Henri-Mondor,
Créteil, France
Purpose: To investigate the effect of massive weight loss on i) knee pain
and disability, ii) low-grade inﬂammation and metabolic status, and iii)
joint biomarkers in obese patients with knee osteoarthritis (OA).
Methods: 140 patients involved in a gastric surgery program were screened
for painful knee OA, and 44 were included (age 44±10.3 years, BMI 50.7±7.2
kg/m2). Clinical data and biological samples were collected before and 6
months after surgery.
Results: Before surgery, IL-6 levels were correlated with levels of hsCRP
(p=0.006) and Helix-II (p=0.01), a biomarker of cartilage turnover, and the
WOMAC function score (p=0.03). Surgery resulted in substantial decrease
in BMI (-20%). Levels of insulin and insulin resistance were decreased at
6 months. Knee pain decreased after surgery (24.5±21 vs. 50±26.6 mm;
p<0.001), and scores on all WOMAC subscales were improved. Levels of IL-
6 (p<0.0001), hsCRP (p<0.0001), orosomucoid (p<0.0001) and ﬁbrinogen
(p=0.04) were decreased after surgery. Weight loss resulted in a signiﬁcant
increase in levels of PIIANP (+32%; p=0.002), a biomarker of cartilage
synthesis, and a signiﬁcant decrease in that of COMP (-36%; p<0.001), a
biomarker of cartilage degradation. Changes in COMP concentration were
correlated with changes in insulin levels (p=0.02) and insulin resistance
(p=0.05).
Conclusions: In obese patients with knee OA, massive weight loss im-
proves pain and function and decreases low-grade inﬂammation. Moreover,
change in levels of joint biomarkers with weight loss suggests a structural
effect on cartilage
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EFFECTS OF LATERAL WEDGE INSOLES ON SYMPTOMS AND STRUCTURAL
DISEASE PROGRESSION IN MEDIAL KNEE OSTEOARTHRITIS: A 12-MONTH
RANDOMISED CONTROLLED TRIAL
K.L. Bennell1 , K.-A. Bowles1, C. Payne2, F.M. Cicuttini3, E. Williamson3,
A. Forbes3, F. Hanna3, R.S. Hinman1
1Univ. of Melbourne, Melbourne, Australia; 2La Trobe Univ., Melbourne,
Australia; 3Monash Univ., Melbourne, Australia
Purpose: Lateral wedge insoles inserted into shoes are an inexpensive,
easily available conservative treatment for knee OA that have been shown
to reduce medial knee joint load. The use of wedge insoles for OA symp-
tomatic beneﬁt is recommended by 13 out of 14 clinical guidelines and it
is proposed that by reducing knee load, wedge insoles may slow disease
progression. Given the limited number of clinical trials in this area, the
main purpose of this study was to investigate whether lateral wedge shoe
insoles lead to greater improvements in knee pain and physical function
and slower structural disease progression than control insoles in people
with medial knee OA.
Methods: This was a randomised participant- and assessor-blinded con-
trolled trial. 200 people aged 50 or more with a clinical and radiographic
diagnosis of mild-to-moderately severe (Kellgren & Lawrence Grade 2-
3) medial knee OA were recruited from the community in Melbourne,
Australia. Participants were randomised into two shoe insole groups: (1)
Full-length 5o lateral wedged insoles or (2) ﬂat control insoles. Both
groups were asked to wear the insoles daily for 12 months. The primary
symptomatic outcome was change in average knee pain in the past week
Abstract 006 – Table 1. ANCOVA results for primary outcomes of pain (cm) and medial tibial cartilage volume (mm3)
Outcome Baseline Follow-up Change (Follow-up – Baseline) Difference†
Wedge Control Wedge Control Wedge Control Est (95% CI) p
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Average pain 4 (2.1) 4.3 (1.9) 3.1 (2.1) 3.1 (2.3) -0.9 (2.1) -1.3 (2.4) 0.34 (-0.27, 0.95) 0.28
Cartilage volume* 1550.2 (451.7) 1520.0 (438.7) 1513.3 (480.1) 1482.8 (431.9) -43.5 (45.5) -43.4 (53.3) -0.38 (-15.38, 14.63) 0.96
*Change refers to the annualized change: (Follow-up minus baseline)/time between scans (yrs). †Adjusted for baseline value.
measured on an 11-point numeric rating scale and the primary structural
outcome was annualised change in medial tibial cartilage volume measured
from MRI. Secondary outcomes included measures of pain, function, health-
related quality of life, physical activity levels, and participant-perceived
rating of change in pain and function. Differences in mean change from
baseline to 52 weeks were compared between groups using analysis of
covariance adjusting for baseline values of the outcome measure. For
annualized change in medial cartilage volume, the data were also analysed
with additional covariates of age, gender, body mass index, medial tibial
bone size and MRI scanner as it was necessary to change scanners part way
through the study.
Results: 89 participants in the lateral wedge insoles group and 90 par-
ticipants in the control insoles group completed the 52-week trial (90%
overall completion rate). There were no baseline differences between the
insole groups except that the control group had a slightly higher BMI.
The results showed no signiﬁcant difference in the primary outcomes of
change in average pain and change in medial cartilage volume over the 52
weeks comparing the groups (Table 1). There was also no difference in the
secondary outcomes nor in the global rating of change. Multiple imputation
to account for missing values did not alter the results.
The mean (SD) duration of daily insole use was signiﬁcantly lower in the
lateral wedge than in the control insole group (6.8 (0.5) hours per day
vs 9.1 (0.4) hours, p<0.0001). More participants reported problems with
wedge insoles (42/89, 47%) than the control insoles (21/90, 23%). The lateral
wedge insoles were also rated as less comfortable than the control insoles.
Conclusions: Lateral wedge insoles worn for 12 months provide no ben-
eﬁts in alleviating symptoms or slowing disease progression (as indicated
by cartilage volume) over control insoles for older adults with mild to
moderately severe medial knee OA. The results do not support the current
recommendations of clinical guidelines.
Trial registration: ACTR12605000503628
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INTRAARTICULAR IL1-RA AFTER ACUTE KNEE INJURY DECREASES
BIOMARKERS OF INFLAMMATION AND IMPROVES PAIN AND FUNCTION
V. Byers Kraus, J. Birmingham, T. Stabler, S. Feng, D.C. Taylor,
C.T. Moorman, W.E. Garrett, A. Toth
Duke Univ., Durham, NC
Purpose: This pilot study evaluated the clinical therapeutic beneﬁts of
intraarticular IL-1 receptor antagonist (IL-1Ra) delivered during the ﬁrst
month after severe acute knee injury with anterior cruciate ligament (ACL)
tear.
Methods: Patients: This study was approved by the Institutional Review
Board and performed under a waiver of IND from the FDA. A total of
11 patients were treated within the ﬁrst 30 days of acute knee injury:
6 patients were randomized to intra-articular IL-1Ra (anakinra 150 mg
intra-articular) and 5 patients to saline placebo (equal volume 1 ml intra-
articular). Patients were recruited a mean 15±7 (SD) days from knee injury
(range 6-27 days). The mean age of participants was 24±4 (SD) years, (6
male, 5 female; 2 African American). Enrollment was limited to patients
under 40 years of age to try to insure the lack of underlying pre-existing
arthropathy. Clinical knee MRIs were performed revealing isolated anterior
cruciate ligament (ACL) tear (partial or full) in all patients: 3 patients
with isolated ACL tear; 3 patients with medial collateral ligament and ACL
tears; 4 patients with meniscal and ACL tears; and 1 patient with medial
collateral ligament, meniscal, and ACL tears.
Biomarker Assays: Samples of synovial ﬂuid (n=9 patients) and serum
(all patients) were available at baseline (prior to injection) and day 28
samples (prior to surgery) and analyzed for IL-1α, IL-1β, and IL-1Ra, using
commercial immunoassays (R&D Quantikine sandwich assays; intra- and
inter-assay CVs were <10%). Serum levels of hyaluronan (HA), associated
with joint inﬂammation, were quantiﬁed using a commercially available
